Skip to main content
Clinical Trials/DRKS00032455
DRKS00032455
Recruiting
Not Applicable

Immune-mediated polyneuropathy/chronic inflammatory demyelinating polyneuropathy (CIDP): diagnostic, prognostic, and treatment-response markers - IP/CIDP-Kohorte

Charité - Universitätsmedizin Berlin0 sites320 target enrollmentFebruary 21, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
G61
Sponsor
Charité - Universitätsmedizin Berlin
Enrollment
320
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 21, 2024
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with CIDP or CIDP variants (DADS, MADSAM, purely sensory/purely motor, focal courses) or other immune\-mediated polyneuropathies \[multifocal motor neuropathy, polyneuropathy of the rheumatic type or chronic inflammatory bowel diseases, chronic inflammatory axonal polyneuropathy (CIAP) , autoimmune (para)nodopathies Guillian Barré Syndrome, polyneuropathies in the context of monoclonal gammopathies of unclear significance, anti\-MAG neuropathies]
  • Age\- and sex\-matched subjects with polyneuropathy of other origin (hereditary, diabetic/toxic origin)
  • control patients of the same age and gender with central demyelinating disease (multiple sclerosis)
  • Age\- and sex\-matched healthy subjects with no other underlying autoimmune\-mediated disease or comorbidities
  • Ability to consent and written informed consent

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials